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Abstract
We have previously demonstrated that gene therapy can rescue the phenotype and extend lifespan in the delta-sarcoglycan
deficientcardiomyopathichamster.Inpatientswithsimilargenetic defects,steroids have been largely used toslow down disease
progression. Aim of our study was to evaluate the combined effects of steroid treatment and gene therapy on cardiac function.
We injected the human delta-sarcoglycan cDNA by adeno-associated virus (AAV) 2/8 by a single intraperitoneal injection into
BIO14.6 Syrian hamsters at ten days of age to rescue the phenotype. We then treated the hamsters with deflazacort. Treatment
was administered to half of the hamsters that had received the AAV and the other hamsters without AAV, as well as to normal
hamsters. Both horizontal and vertical activities were greatly enhanced by deflazacort in all groups. As in previous experiments,
the AAV treatmentalonewasableto preservetheejectionfraction(7067% EF). However, the EF value declined (52614%)witha
combination of AAV and deflazacort. This wassimilarwith all the other groups of affected animals. We confirm that gene therapy
improves cardiac function in the BIO14.6 hamsters. Our results suggest that deflazacort is ineffective and may also have a
negative impact on the cardiomyopathy rescue, possibly by boosting motor activity. This is unexpected and may have
significance in terms of the lifestyle recommendations for patients.
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Introduction
Muscular dystrophies are common and debilitating genetic
diseases that afflict a significant population of children and adults
worldwide [1,2,3,4]. Both skeletal and cardiac muscles are
affected. Not only in patients, but also in carriers [5], cardiomyo-
pathy may be the leading cause of death.
In the last two decades multiple disease mechanisms have been
discovered. The most relevant involves the impairment of the
Dystrophin-glycoprotein complex (DGC) [6].
The DGC plays a central role in maintaining the integrity of the
cell membrane by forming a structural link between the
extracellular matrix and the cytoskeleton, thus protecting the
muscle fibers from contraction-induced damage and necrosis [7].
One member of this complex is delta-sarcoglycan [8] which is a
transmembrane glycoproteinand formsa heterotetrameric complex
together with alpha-, beta-, and gamma-sarcoglycan [9,10,11].
Patients with mutations in the delta-sarcoglycan gene may
present with limb girdle muscular dystrophy 2F [12,13] together
with cardiac involvement [14], or isolated cardiomyopathy
[15,16]. The BIO14.6 hamster [17] is an appropriate model for
the human disease. It displays an absence of delta-sarcoglycan
from the muscle membrane, followed by a deficiency of alpha-,
beta- and gamma-sarcoglycan, reproducing the human LGMD2F
phenotype. This animal model was generated in 1962 [18], when
Homburger fixed by repeated inbreeding a spontaneous trait of
the Syrian hamster characterized by muscular dystrophy and
cardiomyopathy. The strain carries a homozygous 24-kb deletion
of the delta-sarcoglycan gene promoter and the first exon.
At the moment, glucocorticoid treatment [19] is the ‘‘gold
standard’’ for Duchenne Muscular Dystrophy (DMD) and
sarcoglycan defects and has been shown to increase skeletal
muscle strength in DMD patients [20,21].
The commonly used steroids in published trials are prednisone,
prednisolone and deflazacort [22]. The steroid dose used in various
trials for prednisolone, or its equivalent glucocorticoid dose, ranges
from0.9 mg to1.5 mg/kg/day, givendailyor onalternate days, or in
an intermittent (ten days on, ten or twenty days off) regime.
The precise mechanism by which steroids may increase strength
in DMD is not known but their potential beneficial effects include
an inhibition of muscle proteolysis [23], a stabilization of muscle
fiber membranes [24], an increase in myogenic repair [25], an
anti-inflammatory/immunosuppressive effect [26], a reduction of
cytosolic calcium concentrations [27], an upregulation of utrophin
[28] and a differential regulation of the genes in the muscle fibers
[21].
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the progression of myocardial fibrosis in mdx mice [29]. One study
has suggested that anti-inflammatory therapy with oral deflazacort
has beneficial effects on the left ventricular function in DMD
patients [30]. Another work has shown that long-term deflazacort
therapy might be a valuable tool to minimize the progression of
cardiomyopathy in DMD patients [29]. However, the effect of
corticosteroids on cardiac function in patients with LGMD2C-F
remains largely unknown. Bauer et al. [31] have shown that in Sgcd-
null mice prednisolone treatment induces a decompensation of
global heart function which is associated with an increase in the
myocardial pathology.
Gene vectors derived from adeno-associated viruses (AAV) are
among the most promising systems for muscle and heart gene
delivery [32,33]. In the last few years, several studies have shown
how a single [34] or a double systemic injection [35] of different
AAV pseudotypes can restore the expression of delta-sarcoglycan
cDNA in male BIO14.6 hamsters. This treatment was able to
rescue the cardiomyopathy and prolong the lifespan in this model.
We previously demonstrated that AAVs are well tolerated in
hamsters [35] and there is a very weak immune reaction against a
specific capsid or delta-sarcoglycan, maybe for the similarity with
other sarcoglycans [36].
However, no information is available on the combinatorial
therapy including both gene therapy and steroids. In our present
research we have tested the effects of long-term deflazacort
treatment upon phenotype rescued by gene therapy.
Results
Population study
To test the combination of gene treatment and corticosteroids,
we created six groups of hamsters (Figure 1):
Group BIO14.6AAV (n=11) were BIO14.6 hamsters intraper-
itoneally treated at 10 days of age with AAV2/8-CMV-hSCGD
without any other treatment.
Group BIO14.6AAV+DEF (n=11) were BIO 14.6 hamsters
intraperitoneally treated at 10 days of age with AAV2/8-CMV-
hSCGD and treated starting at 6 weeks of age using 5 cycles of
deflazacort for 3 weeks followed by 3 weeks of interval.
Group BIO14.6+DEF (n=15) BIO14.6 hamsters that were
treated starting at 6 weeks of age using 5 cycles of deflazacort for 3
weeks followed by 3 weeks of interval.
Group BIO14.6 (n=15) BIO14.6 hamsters not treated.
Group GS+DEF (n=6) controls Golden Syrian hamsters that
were treated starting at 6 weeks of age using 5 cycles of deflazacort
for 3 weeks followed by 3 weeks of interval.
Group GS (n=6) controls Golden Syrian hamsters not treated.
Delta sarcoglycan expression
To test the expression of transgene human delta-sarcoglycan, we
analyzed tissue, of some animals, extracts by western blot analysis
(Figure 2a), using a monoclonal Ab against human delta-sarcoglycan
that cannot detect the hamster protein in wild-type animals because it
recognizes a human-specific N-terminal epitope.
Our results show that, similarly to previous results [35], a single
injection of AAV8-CMV-hSCGD vector in 10-days-old neonatal
BIO14.6 hamsters, achieved a nearly complete gene transfer in the
heart. The expression was tested by WB in the BIO14.6AAV
group compared with BIO14.6AAV/DEF group, 10 days after
starting the first cycle of deflazacort at the dose of 1.5 mg/kg/day
(Figure 2a).
Cardiac muscle pathology
To assess the rescue of the normal cardiac structures we
sacrificed animals from BIO14.6AAV and BIO14.6AAV +DEF
Figure 1.Timeline of the experimental procedures for the different groups of hamsters. BIO14.6 AAV: hamsters injected at 10 days of age
with delta-sarcoglycan by AAV2/8; BIO14.6 AAV+DEF: hamsters injected at 10 days of age with delta-sarcoglycan by AAV2/8 and with deflazacort at 6
weeks of age; BIO14.6+DEF: hamsters treated with deflazacort at 6 weeks of age; BIO14.6: hamsters not treated; GS: Golden Syrian hamsters as health
control; GS+DEF: Golden Syrian hamsters treated with deflazacort at 6 weeks of age.
doi:10.1371/journal.pone.0024729.g001
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observe any evident dilation in hearts explanted by BIO14.6AAV
hamsters, as a further confirmation of the efficacy of the systemic
gene therapy[34,35]. However heart dilation was observed in
BIO14.6AAV+DEF animals (Figure 2b). Analogously, sections
from all groups of BIO14.6 hamsters showed differences by
haematoxylin-eosin (Figure 2c) and Masson’s Trichrome staining
(Figure 2d) due to the presence of necrotic and fibrotic areas. As
expected, GS hamsters were completely normal and DEF
treatment did not modify histology (Figure S1).
We identified more fibrotic areas in group BIO14.6 in
comparison with BIO14.6 AAV. Again, pathology in BIO14.6A
AV+DEF was more similar to BIO14.6 than to BIO14.6AAV.
Weight and activity
The body weight was reduced in affected hamsters at all time
points as compared to normal animals (Figure 3a). Deflazacort
treatment further reduced body weight, independently on the age
of the animals and on the genotype. No difference in the appetite
was observed. In particular weight was reduced of 10–20%
between BIO14.6AAV and BIO14.6AAV+DEF, was reduced 20–
25% between BIO14.6 and BIO14.6+DEF and also by 10-20%
between GS and GS+DEF [Group (F5/33 = 29.502, p,0.0001);
Test session (F2/66 = 100.303, p,0.0001); Group x Test session
(F10/66 = 2.38, p=0.017)]. Despite this side effect, prolonged
treatment with deflazacort improved all behavioral functions
measured in normal and affected animals. As reported in the
Figures 3b and 3c, affected hamsters reduced both vertical and
horizontal exploratory behavior in a novel environment as com-
pared to normal animals. Animals treated with deflazacort
increased vertical activity [Group (F5/31 = 6.47, p=0.0003);
Test session (F2/62 = 4.89, p=0.01)] and distance traveled in the
open field [Group (F5/37=3.57, p=0.0098); Test session (F2/74
= 2.603, p=0.08)] independently on their age and genotype.
Cardiac function
None of the animals died during the study. No difference in
heart rate was found among the population study. Table 1 shows
all measured cardiac parameters values. BIO14.6AAV group
showed statistically significant improvement in EF (Fig. 4a) (7067
vs 52614; 4866; 4768%; =0,03), FS (3565 vs 2368; 21611;
21615%; p=0,04), LVEDd (5.2060.85 vs 5.7660.88; 6.356
0.59; 6.3260.79 mm; p=0,03) (Fig. 4b) and LVESd (3.4160.70
vs 4.3961.13; 5.0360.80; 5.0361.01 mm; p=0,03) with respect
to BIO14.6AAV+DEF (n=5) group, BIO14.6+DEF (n=11)
group and BIO14.6 (n=12) group respectively. No significant
Figure 2. Expression of the injected delta-sarcoglycan and necrotic and fibrotic areas in the heart: (a) Expression of human delta-
sarcoglycan assessed by WB analysis in the hearts respectively of a positive control of transduction (CRT+), negative control (CRT-), BIO14.6 AAV and
BIO 14.6 AAV+DEF 6 weeks after AAV delivery (,8 weeks). (b) Explanted hearts from BIO 14.6 AAV and BIO 14.6 AAV+DEF hamsters at 9 months of
age. The heart dilation of a BIO14.6AAV+DEF hamster is evident if compared with a BIO14.6 AAV hamster. (c) Hematoxylin-eosin staining on
cryosections of the hearts of BIO14.6 AAV 6 weeks after AAV delivery, BIO 14.6 AAV at 9 months, BIO14.6 AAV+DEF at 9 months, the healthy control
(GS hamsters) and the untreated BIO14.6 hamsters. (d) On the same groups of hamsters we performed Masson’s trichrome staining on a cryosection
of the heart. (10 mm).
doi:10.1371/journal.pone.0024729.g002
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between BIO14.6+DEF group and BIO14.6 (p=0.1). Compared
to BIO14.6+DEF group and BIO14.6 group, BIO14.6AAV+DEF
group showed increased EF (52614 vs 4866; 4768) and reduced
LVEDd (5.7660.88 vs 6.3560.59 vs 6.3260.79). GS hamsters
were completely normal and DEF treatment did not modify
parameters (Table S1).
Discussion
The delta-sarcoglycan deficient BIO14.6 hamster is one of the
most commonly studied models for inherited dilated cardiomyop-
athy and muscular dystrophy. In contrast to humans, cardiomy-
opathy in hamsters occurs with a significantly higher severity than
muscular dystrophy and is the cause of premature death at about
one year of age. We have previously demonstrated that the
systemic transfer of the human delta-sarcoglycan cDNA, by using
a combination of AAV vectors [35], brings to the rescue of the
BIO14.6 cardiomyopathy and muscular dystrophy. While AAVs
are curative for animals, no human patient has been treated thus
far by systemic injections at full dosage.
Gene therapy by AAVs has been already used to treat genetic
human blindness [37]. At the moment, muscular dystrophies are
only treatable in animal models, because there are some inherent
difficulties in humans, due to the huge muscle mass, as compared
with retina. However, local injections of AAV containing alpha-
sarcoglycan have been used successfully [38]. In the next future,
improvements in vector preparations and safety will promote
clinical trials with systemic injections of AAV. At present, oral
steroids are the only effective long-term drug therapy known for
human muscular dystrophies. Prolonged ambulation, reduced
scoliosis, and improved pulmonary function have been attributed
to steroid use [39]. In addition, the use of corticosteroids has also
shown the improvement in left ventricular function in Duchenne
Muscular Dystrophy (DMD) patients, as previously described
[30,40]. As oral corticosteroids have been used in DMD and in
sarcoglycanopathies, we decided to conduct a series of experiments
to test the combination of gene therapy and long-term glucocor-
ticoid treatment in the delta-sarcoglycan deficient BIO14.6
hamster. To avoid measuring deleterious side effects caused by
steroids, we paid attention to the following points: 1) starting the
treatment 6 weeks after birth when the adult sexual development is
just complete; 2) using deflazacort instead of prednisone to reduce
sodium-retention effects and weight gain [41,42]; 3) applying a low
dose (scaling down to 0.3mg/kg) which should not be immuno-
suppressive, and 4) adopting an intermittent schedule of three
weeks of treatment, followed by three weeks of suspension from the
treatment. Most of these points have also been considered in
human trials to limit the toxicity and side effects in muscular
dystrophy patients.
Following AAV treatment, the expression of the human delta-
sarcoglycan was confirmed by western blot analyses. This
expression decreased with time, as previously shown, in the
Figure 3. Weight and activity. (a) Body Weight of GS, GS+DEF, BIO14.6, BIO14.6+DEF, BIO14.6AAV and BIO14.6AAV+DEF hamsters in three
different test sessions;(b) Vertical activity of GS, GS+DEF, BIO14.6, BIO14.6+DEF, BIO14.6AAV and BIO14.6AAV+DEF hamsters in three different test
sessions;(c) Horizontal activity of GS, GS+DEF, BIO14.6, BIO14.6+DEF, BIO14.6AAV hamsters in three different test sessions. # p$0.05 ; *p,0.05 vs.
BIO14.6.
doi:10.1371/journal.pone.0024729.g003
Table 1. Echocardiographic parameters in the different
groups of hamsters at 9 months of age HR= heart rate; IVST
= Inter Ventricular Septal Thickness; LVEDd = Left Ventricular
End Diastolic Diameter; LVESd = Left Ventricular End Systolic
Diameter; PWT = posterior wall thickness; FS = Fractional
Shortening; EF = Ejection fraction.
Parameters
BIO14.6
AAV
BIO14.6
AAV+DEF
BIO14.6+
DEF BIO14.6
HR (beats/min) 365620 382632 389627 390630
IVST (mm) 1.1660.20 1.1260.13 1.0460.06 1.1160.12
LVEDd (mm) 5.2060.85 5.7660.88 6.3560.59 6.3260.79
LVESd (mm) 3.416 0.70 4.3961.13 5.0360.80 5.0361.01
PWT (mm) 1.1860.11 1.3360.23 1.1960.11 1.1960.09
FS (%) 35652 3 682 1 611 21615
EF (%) 70675 2 614 48664 7 68
doi:10.1371/journal.pone.0024729.t001
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was not significant for the present study, since all the animals
were sacrificed at 9 months of age, when differences in the
lifespan are not yet evident. In fact, at 9 months of age, both the
affected and non-affected hamsters were still alive, irrespective of
the delta-sarcoglycan mutation. Differences were, however,
evident for heart dilation and function, as demonstrated by
echocardiography.
In the group of hamsters treated with AAV(BIO14.6AAV group)
we found an improvement in the ejection and shortening fraction
and a reduction in the left ventricular systolic and diastolic
diameters. These parameters are close to those of GS hamsters
and a proof of rescue. We found no evident differences in car-
diac function and diameters between BIO14.6 group and BIO
14.6+DEF group. According to these findings, we show that the
deflazacort treatment did not contribute to the cardiomyopathy
Figure 4. Echocardiographic changes after gene and deflazacort therapy in the different groups of hamsters. (a) ejection fraction (EF)
(b) LEVDd respectively in the BIO 14.6 AAV, BIO14.6 AAV+DEF, BIO14.6 +DEF and BIO14.6 hamsters at 9 months. Statistical significance is calculated in
comparison with the BIO14.6 group.
doi:10.1371/journal.pone.0024729.g004
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which prednisolone [31] caused deterioration of the myocardial
function and this was probably linked to due to additional
mineralocorticoid effects [42] that should be avoided using
deflazacort. In contrast the BIO14.6AAV+DEF group, we showed
a minimal and not statistically significant change in cardiac
function, despite the gene therapy. This result was surprising, since
theAAVplus deflazacorttreatment reported a phenotypevery close
to that observed in the affected hamsters that had received no
treatment. Deflazacort treatment produced no prompt modification
in the expression of delta-sarcoglycan in the heart, as result of a
rapid transcriptional inhibition (Figure 2a); in addition, no
reduction in the genomic copies of AAV was seen at 9 months
(Figure S2),as a resultoflong-termeffects ontheAAV turnover. On
thesebases,weobserve thatthereisnoapparent effect ofdeflazacort
on the gene therapy efficacy. However, we cannot exclude the
possibility that the steroid treatment can produce a late-onset
transcriptional inhibition of the vector promoter in the heart.
The worsened evolution of the cardiomyopathy may have several
alternative explanations. It may be due to 1) a possible increase of
the animal activity in the cages; 2) an increase in the blood pressure,
or 3) water and sodium retention. Our behavioral experiments
suggest that the treatment with deflazacort has a strong effect in
reducing body weight and intensifying exploratory behavior up to
+100%, as well as motility in both BIO14.6 hamsters and control
animals. However, further studies are required to evaluate long-
term effects by steroids also in other animal models.
We do not know whether this augmented activity can be
detrimental in terms of heart failure, but it has been reported that
ambulant Becker Muscular Dystrophy patients more often develop
a dilated cardiomyopathy and that DMD carriers (with 50% of
fibers not expressing dystrophin) have a normal motor activity,
although they still develop a cardiomyopathy. An alternative
hypothesis is related to increased fluid retention and/or an
increase in blood pressure with glucocorticoids. We did not
observe statistically significant variations in the pressure, but the
average value could be slightly increased for a long time. However,
it is important to note that we used a low dosage of deflazacort and
the treatment was concluded two months before sacrifice. We
cannot exclude that a possible effect of deflazacort on gene therapy
may be dependent on increased ER stress and cell stress, but a
number of other experiments in further model systems are
required to solve this issue.
The improvement obtained by gene therapy can be reversed
(totally or partially) by combining gene therapy to glucocorticoid
therapy. Is this phenomenon limited to the hamster or can it also
be observed in humans? In the former hypothesis, one should
consider how much wrong scientific information can derive from
studies with animal models. In the latter hypothesis, it may be
important to evaluate whether future improvements in the
deambulation of muscular dystrophy patients may result in a
worsening of the cardiomyopathy.
This is the first study that compares the effect of corticosteroids
in animals treated with gene therapy and that demonstrates the
harmful effect of the combination of these therapies. Our preferred
hypothesis is that the enhancement of activity caused by
corticosteroid use and gene therapy together causes an excessive
heart stress resulting in an increased risk of cardiac failure.
Materials and Methods
AAV vector Construction and production
The human delta-sarcoglycan (SG) gene was cloned into the
plasmid pAAV-2.1CMV-EGFP. Recombinant AAV vector con-
taining human delta-sarcoglycan cDNA, driven by the cytomeg-
alovirus (CMV) promoter, was constructed by standard cloning
protocols and were packaged into 2/8 serotype. The resulting
pAAV2.1-CMV-delta-SG was transfected in sub-confluent 293
cells along with the pAd-Helper and the pack 2/8 packaging
plasmid, as described previously [43]. The recombinant AAV2/8
vector was purified by two rounds of CsCl, as described previously.
Vector titers, expressed as genome copies per milliliter (GC/ml),
were assessed by real-time PCR (ABI 7900 Real Time PCR
System), as described previously [44].
Experimental animals
All the animals were male Syrian hamsters belonging either to
strain BIO14.6 (cardiomyopathic) or BIO Golden Syrian Control
hamster that is a model for BIO hamster mutants and hybrids.
These were purchased from Bio Breeders INC, Fitchburg, Mass
(http://www.biobreeders.com) that guarantees homogeneous pure
genetic background.
Ethics Statement
All procedures on wild-type Bio Golden Syrian and dystrophic
BIO14.6 hamsters were approved by the ‘‘Ministero della Salute’’
Committee Rome, Italy for ‘‘Good Animal experimental Activi-
ties’’. The investigation conforms to the European Commission
Directive 86/609/EEC. Protocol ID 0003092/10/CB.
Drugs and Devices
Deflazacort (Sanofi-Aventis S.p.A) was administered per os with
medical food (Mucedola s.r.l). Every three weeks this food was
replaced by normal food. We used 1.5 mg/kg in the first cycle,
0.75 mg/kg in the second cycle and 0.3 mg/kg from the third
cycle onwards. Both food preparations were humidified to confer a
similar appearance and taste. The food was weighed every day.
Western Blotting
Hamsters were euthanized by inhalation in a CO2 chamber by
skilled staff. The hearts were rapidly explanted excising the aorta
and processed by skilled staff using standard procedure: i.e., they
were rinsed in cold phosphate-buffered saline (pH 7.4) containing
0.16 mg/mL heparin to remove red blood cells and clots, frozen in
liquid nitrogen, and stored at 270uC. The hearts, muscles or other
tissues were homogenized in a lysis assay buffer (Urea 8M, SDS
4%, 125 mM Tris HCl pH 6.8). The samples were separated on
sodium dodecyl sulphate - 10% polyacrylamide gel electrophoresis
and transferred to nitrocellulose membrane. After blocking in 10%
non fat dry milk in Tween-Tris-Buffered Saline (TTBS-1X) buffer
(10mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20) for 1 h, the
membranes were incubated with primary antibodies in TTBS 1X
at room temperature for 1.5 h. The monoclonal antibody
recognizing a human epitope of delta-sarcoglycan was used in
this experiment with a 1:25 dilution. Following primary antibody
incubation and rinses, the membranes were incubated with the
secondary antibody, goat anti-mouse immunoglobulin conjugated
with horseradish (Sigma), with 1:10,000 dilution in 0.5% dry milk
and TTBS 1X. After 45 min of antibody incubation and five
washes with TTBS 1X buffer, the delta-sarcoglycan protein band
was visualized with a chemiluminescence reagent (Supersignal,
WestPico, Pierce) and exposed to X-ray film.
Histology
Tissue samples were collected 6 weeks after AAV injection and
at 9 months of age. Samples were processed by cryosections at 7-
to 10- mm thickness.
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washed in Phosphate-buffered saline (PBS- 1X) buffer (10 mM
Tris-HCl, 200mM NaCl, 0.05% NP 40, 0.05% Tween 20) and
stained in haematoxylin for 4 min and in eosin for 6 min.
Cryosections were dried in ethanol, fixed in xylene, and mounted
with the EUKITT mounting kit (O.Kindler GmbH & CO).
Masson’s trichrome staining
Cryosections of muscular tissues were fixed in Bouin’s Solution at
56uC for 15 min, cooled and washed in running tap water to
remove the yellow colour from the section. They were stained in
Working Weigert’s Iron Haematoxylin Solution for 5 min, washed
in running tap water for 5 min and stained in Biebrich Scarlet- Acid
Fucsin for 5 min, then rinsed in deionised water, placed in Working
Phosphotungstic\Phosphomolybdic acid solution for 5 min, stained
in Aniline Blue solution for 5 min and in acid acetic 1% for 2 min.
Behavioral Testing
The behavioral testing room had constant sound and light
background. Animals were tested during their light phase, between
9.00 am to 5.00 pm. Before each behavioral task, animals were
acclimatized to the testing room for at least 30 min.
General motor activity was measured in an activity cage (Ugo
Basile, Italy), with metal floor and Plexiglas transparent walls,
covered with white paper. At the beginning of the measurement,
each hamster was released from the center of the activity cage.
Hamsters were tested for 20 min, during which vertical activity,
leaning (standing on the hindlimbs with both forelimbs on the wall)
and rearing (standing on the hindlimbs with no support for the
forelimbs), was measured by a system of photo beam located on
the wall of the cage (Ugo Basile, Italy). Horizontal activity was at
the same time automatically scored by a video tracking system
(ANY-MAZE, Stoelting, USA) and quantified as distance (m)
travelled by the animals in the 20 min interval. Animals were
tested during the last week of the deflazacort treatment.
Statistical analyses
Two-way ANOVA, for repeated measures, with a between-
group factor (6 levels: 6 levels: BIO14.6AAV, BIO14.6AAV+DEF,
BIO14.6+DEF, BIO14.6, GS+DEF and GS) and test sessions (3
levels: T1, T2, T3) as repeated measure, was used to analyze the
body weight, the mean number of vertical activity, and the mean
distance travelled. Fisher LSD post hoc test was used to compare
the different groups. Statistical significance was set at p,0.05.
Echocardiographic study
Hamsters were anaesthetized with Isoflurane (Isf) to produce
general anesthesia with minimal cardiovascular depression. Isf was
administered with the use of a vaporizer and was performed by the
same individual over a 1-min period in an isolation chamber with
5.0% Isf in 100% O2; the anesthesia was maintained during
spontaneous breathing of 1.25% Isf in 100% O2 at a flow rate of 1
l/min via a small nose cone. A small plastic bag surrounding the
nose cone was attached to wall suction and scavenged excess gas.
Left parasternal and left apical echocardiographic images of
anaesthetized hamsters lying in the dorsal recumbent position
were obtained using the GE Vivid 7 (General Electric, VingMed,
Horten, Norway) and an high-frequency probe (30-Mhz) with high
frame rate images (80 frames/heartbeat; temporal resolution
2.5 msec). This frame rate is high enough to get reliable velocity
and deformation traces. Care was taken to avoid applying
excessive pressure, which can induce bradycardia and cardiac
arrest. 1-cm region of interest was expanded, allowing high frame
rates, and the gain and compression were set for optimal imaging.
The chest hair is removed with a topical depilatory agent. All
echocardiographic measurements were performed, according to
the American Society of Echocardiography recommendations
[45], by the same investigator (G.N.) blinded to hamsters clinical
status. For intra- and inter-observer variability of analysis, all
images were digitally stored and reviewed off-line by and
independent observer (V.R.) who had experience in echocardio-
graphic analysis of rodent heart. The three-lead electrocardiogram
(ECG) was recorded from the front limbs and the right hind limb.
Two-dimensional guided M-mode imaging was used to measure
the LV end-systolic (LVESd) and end-diastolic (LVEDd) diame-
ters, interventricular septal thickness (IVST) during diastole and
posterior wall thickness (PWT) during diastole, all in the short-axis
view at the level of the papillary muscles. The angle of
interrogation of the M-mode beam was carefully aligned to be
perpendicular to the LV walls at the antero-posterior axis;
LVEDd, IVST and PWT were measured by the leading edge
method, and the LVESd was measured at the posterior wall’s time
of maximum anterior motion. Three representative cardiac cycles
were analyzed and the mean values for each measurement were
recorded. LV systolic function was assessed by ejection fraction
(EF; %), calculated from these measurements by an automated
computer program which displays the output as EF and by
fractional shortening (FS; %) which was calculated from the M-
mode echocardiogram using the equation defined as (LVEDd -
LVESd)/LVEDd x 100.
Supporting Information
Figure S1 H-E staining of heart sections of GS and GS +DEF
hamsters at 9 months.
(TIF)
Figure S2 Genomic copy number of AAV/mg of tissue
extracted from hamster hearts at 9 months of age. The dotted
line is the average background value observed with AAV-negative
tissue, using real-time PCR.
(TIF)
Table S1 Echocardiographic parameters in GS and GS+DEF
hamsters at 9 months of age HR= heart rate; LVEDd = Left
Ventricular End Diastolic Diameter; LVESd = Left Ventricular
End Systolic Diameter; FS = Fractional Shortening; EF =
Ejection fraction.
(DOC)
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